OSM elisa kit

AVISCERA BIOSCIENCE

HOME ::

Human Oncostatin M (OSM) ELISA
Oncostatin M is A Biomarker for cardiovascular diseases and tumor. Oncostatin M is a exercise-induced myokine to inhibit cancer cell growth.
Alternative name: MGC20461 A ligand of gp130 interleukin-6-type cytokine
Oncostatin is a growth regulator. Inhibits the proliferation of a number of tumor cell lines. OSM stimulates proliferation of AIDS-KS cells. It regulates cytokine production, including IL-6, G-CSF and GM-CSF from endothelial cells. OSm uses both type I OSM receptor (heterodimers composed of LIPR and IL6ST) and type II OSM receptor (heterodimers composed of OSMR and IL6ST). OSM was Involved in the maturation of fetal hepatocytes, thereby promoting liver development and regeneratio. Recently oncostatin M is reported as an exercise induced myokine to inhibit cancer cell growth.
Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth
Regular physical activity protects against the development of breast and colon cancer, since it reduces the risk of developing these by 25-30%. During exercise, humoral factors are released from the working muscles for endocrinal signaling to other organs. We hypothesized that these myokines mediate some of the inhibitory effects of exercise on mammary cancer cell proliferation. Serum and muscles were collected from mice after an exercise bout. Incubation with exercise-conditioned serum inhibited MCF-7 cell proliferation by 52% and increased caspase activity by 54%. A similar increase in caspase activity was found after incubation of MCF-7 cells with conditioned media from electrically stimulated myotubes. PCR array analysis (CAPM-0838E; SABiosciences) revealed that seven genes were upregulated in the muscles after exercise, and of these oncostatin M(OSM) proved to inhibit MCF-7 proliferation by 42%, increase caspase activity by 46%, and induce apoptosis. Blocking OSM signaling with anti-OSM antibodies reduced the induction of caspase activity by 51%. To verify that OSM was a myokine, we showed that it was significantly upregulated inserum and in three muscles, tibialis cranialis, gastronemius, and soleus, after an exercise bout. In contrast, OSM expression remained unchanged in subcutaneous and visceral adipose tissue, liver, and spleen (mononuclear cells). We conclude that postexercise serum inhibits mammary cancer cell proliferation and induces apoptosis of these cells. We suggest that one or more myokines secreted from working muscles may be mediating this effect and that OSM is a possible candidate. These findings emphasize that role of physical activity in cancer treatment, showing a direct link between exercise-induced humoral factors and decreased tumor cell growth.
Hojman P, et al. Am J Physiol Endocrinol Metab. 2011 Sep;301(3):E504-10. doi: 10.1152/ajpendo.00520.2010. Epub 2011 Jun 7.
Vascular effects of glycoprotein130 ligands--part II: biomarkers and therapeutic targets
Glycoprotein130 (gp130) ligands are defined by the use of the common receptor subunit gp130 and comprise interleukin (IL)-6, oncostatin M (OSM), IL-11, leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CLC), ciliary neurotrophic factor (CNTF), IL-27 and neuropoietin (NP). In part I of this review we addressed the pathophysiological functions of gp130 ligands with respect to the vascular wall. In part II of this review on the vascular effects of gp130 ligands we will discuss data about possible use of these molecules as biomarkers to predict development or progression of cardiovascular diseases. Furthermore, the possibility to modulate circulating levels of gp130 ligands or their tissue expression by specific antibodies, soluble gp130 protein, renin-angiotensin-aldosterone system (RASS) inhibitors, statins, agonists of peroxisome proliferator-activated receptors (PPAR), hormone replacement therapy, nonsteroidal anti-inflammatory drugs (NSAID) or lifestyle modulating strategies are presented. Recent knowledge about the application of recombinant cytokines from the gp130 cytokine family as therapeutic agents in obesity or atherosclerosis is also summarized. Thus the purpose of this review is to cover a possible usefulness of gp130 ligands as biomarkers and targets for therapy in cardiovascular pathologies.
Demyanets S, Huber K, Wojta J. Vascul Pharmacol. 2012 Aug 19;57(1):29-40. Epub 2012 Jan 8.
Relation between neonatal jaundice and oncostatin M, hepatocyte growth factor and soluble gp130 levels in umbilical cord
OBJECTIVES: Oncostatin M (OSM), hepatocyte growth factor (HGF) and soluble glycoprotein 130 (sgp130) have been demonstrated to be involved in fetal liver development. In this study, we examined the relation between neonatal jaundice and OSM, gp130 or HGF levels in umbilical cord blood. DESIGN: A cross-sectional study of 160 neonates born at Okayama University Hospital. SETTING:Tertiary referral center serving a population of three million. METHODS:The serum concentrations of OSM, HGF and sgp130 in umbilical venous cord blood were measured and compared with the clinical records of these neonates. RESULTS:The HGF level was correlated to both gestational week (p=0.007) and birthweight (p=0.015), as well as to total bilirubin on Day 1 (p=0.032). In preterm neonates, the HGF levels were lower in neonates who received phototherapy (photo group) than in those who did not receive phototherapy (non-photo group) (p=0.002). In contrast, in term neonates, OSM levels were lower in the photo group than in the non-photo group (p=0.0003). CONCLUSIONS:These findings suggest that the phototherapy requirement for neonatal jaundice may be associated with lower umbilical HGF concentration in preterm neonates and with lower umbilical OSM concentration in term neonates.
Nakatsukasa H, et al. Acta Obstet Gynecol Scand. 2008;87(12):1322-8.

	Human Oncostatin M (OSM) ELISA KIt Code No.: SK00509-01 Size: 96 T Price: $460.00 USD Standard range: 15.6-1000 pg/ml Sensitivity: 7.8 pg/ml Sample Type: serum, plasma Sample require: 100 uL per well Intra-CV:4-6% Inter-CV: 8-10% Protocol: PDF
More IL-6 superfamily and gp130 ligaands related Proteins
IL-6 CNTF CLCF1 gp130 LIF oncostatin M (OSM) IL-11 IL-27

elisa kIT elisa kIT elisa kIT elisa kIT

Name	Code No.	Size	Price ($)
Oncostatin M (OSM) (Human) ELISA KIT	SK00509-01	96 T	360.00
Oncostatin M (OSM) (Human) recombinant	00509-02-100	100 ug	360.00
Anti Oncostatin M (OSM) (Human) IgG	A00509-02-100	100 ug	260.00
Anti Oncostatin M (OSM) (Human) IgG	A00509-02-50B	50 ug	320.00